// App-Quantinova.ai

5058 : Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant-prostate-cancer (mCRPC).

Researchers

Presenter

  • Raya Leibowitz-Amit

Principal Investigators

  • Arnoud J. Templeton

  • Eshetu G. Atenafu

  • Francisco Emilio Vera-Badillo

  • Muralidharan Chllamma

  • Henry L. Solow

  • Jennifer J. Knox

  • Ian Tannock

  • Srikala S. Sridhar

  • Anthony Michael Joshua

Medical Centers

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved